Abbvie Inc

Research Abbvie Inc (ABBV) on Bullrun: valuation model: 66.2% overvalued, market cap USD 449.31B, P/E 125.4, dividend yield 2.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerABBV
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-General
• CurrencyUSD
• Valuation signal66.2% overvalued
• Market capUSD 449.31B
• P/E125.4
• Dividend yield2.7%
• Financial periodFY2025
• RevenueUSD 61.16B
• Revenue growth8.6%
• Net incomeUSD 4.23B
• Free cash flowUSD 17.82B
• Gross margin70.2%

Valuation Snapshot

Bullrun's latest valuation model marks Abbvie Inc as 66.2% overvalued; latest market cap is USD 449.31B; P/E is 125.4; dividend yield is 2.7%.

About Abbvie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.

Frequently asked questions

Is Abbvie Inc overvalued or undervalued?

Bullrun's valuation model currently marks Abbvie Inc as 66.2% overvalued.

What is Abbvie Inc's market cap?

Abbvie Inc's market capitalization is USD 449.31B.

What is Abbvie Inc's P/E ratio?

Abbvie Inc's price-to-earnings (P/E) ratio is 125.4.

Does Abbvie Inc pay a dividend?

Abbvie Inc has a dividend yield of 2.7%.

What does Abbvie Inc do?

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases;